No Data
AUDITED ACCOUNTS AS AT 31 DECEMBER 2024
luye pharma (02186): The antidepressant class 1 innovative drug (LY03021) has been approved to conduct clinical trials.
Luye Pharma (02186) announced that the group's first category of innovative drug LY03021 has obtained approval from China's National Medical Products Administration...
UNAUDITED SEMI-ANNUAL REPORT FOR THE PERIOD ENDED 30 JUNE 2024
AUDITED ACCOUNTS AS AT 31 DECEMBER 2023
Fubon FTSE Taiwan RIC Capped Index ETF: UNAUDITED SEMI-ANNUAL REPORT FOR THE PERIOD ENDED 30 JUNE 2023
Fubon FTSE Taiwan RIC Capped Index ETF: AUDITED ACCOUNTS AS AT 31 DECEMBER 2022